Tresiba vs Lantus: A Practical Breakdown for Patients

Tresiba at a glance:

• Drug class: Ultra-long-acting basal insulin analog
• Manufacturer: Novo Nordisk
• FDA approved: 2015
• Route: subcutaneous injection (FlexTouch pen)
• Typical frequency: once daily; flexible timing
• Half-life: ~25 hours (duration of action >42 hours)
• Cash price (US): ~$420–$480/month list; $35/month cap for Medicare beneficiaries

Tresiba comparison pages tend to overstate the differences. The honest take is that most well-established options in this space are similar enough that insurance coverage, prescriber familiarity, and personal preference matter more than head-to-head efficacy.

Mechanism

Tresiba: Insulin degludec forms soluble multi-hexamers in subcutaneous tissue that release slowly into circulation, producing a flat duration of action exceeding 42 hours.

Lantus: Insulin glargine is a long-acting analog. After subcutaneous injection it forms microprecipitates that release slowly, producing a relatively flat 24-hour profile without a pronounced peak.

For people new to this comparison, the practical takeaway is that the underlying mechanisms are different enough that response can vary.

Dosing & Administration

Effectiveness

Tresiba: Comparable A1c reduction to glargine with significantly lower rates of nocturnal hypoglycemia (DEVOTE).

Lantus: 24-hour basal glucose control with reduced nocturnal hypoglycemia vs NPH.

In head-to-head comparisons (where they exist), the higher-dose newer agents tend to outperform older ones — sometimes meaningfully. Reference trials: DEVOTE (Marso 2017, NEJM) — non-inferior cardiovascular safety vs glargine; 40% lower nocturnal severe hypoglycemia for Tresiba; Riddle MC et al for Lantus.

Side Effects

The two compounds have overlapping side-effect profiles. Common to both:

• hypoglycemia
• weight gain
• injection-site reactions
• lipodystrophy with poor rotation

Important risks worth knowing for both:

• severe hypoglycemia
• diabetic ketoacidosis if dosing is interrupted in T1D

Cost

Tresiba: ~$420–$480/month list; $35/month cap for Medicare beneficiaries. Lantus: ~$280–$340/month list; $35/month cap for Medicare beneficiaries; biosimilar (Semglee) available at lower cost.

Insurance coverage and manufacturer programs change the relative cost picture significantly. See our individual cost guides for Tresiba cost and Lantus cost for the latest numbers.

Which Is Right for You?

The practical decision usually comes down to four factors:

1. What's covered by your insurance? Often the deciding factor
2. What does your prescriber have experience with? Familiarity reduces dosing errors
3. How comfortable are you with injections (or oral dosing if applicable)?
4. What's your tolerance for side effects?

If you and your clinician end up split between Tresiba and Lantus, either is a defensible choice in most cases.

Switching Between Them

Switching from Tresiba to Lantus (or the reverse) is usually straightforward but should be done with clinician guidance — particularly to align dose escalation and avoid GI side effects from re-titration.

Bottom Line

Don't overthink the Tresiba vs alternative decision. Both produce results; the difference is usually smaller than the discussion implies.

Frequently Asked Questions

Related Reading

• Tresiba Explained: How It Works and Who It's For
• Tresiba Side Effects in 2026: Real Reports, Real Solutions
• Real Tresiba Results: What 6 and 12 Months Actually Look Like
• Tresiba Cost in 2026: What You'll Actually Pay (Real Numbers)
• Is Lantus Right for You? An Evidence-Based Breakdown
• What Is Humalog? Everything You Should Know Before Starting

Sources

• American Diabetes Association. Standards of Care in Diabetes — 2024. Diabetes Care 2024;47(Suppl 1).
• Heise T et al. Insulin Pharmacokinetics and Pharmacodynamics. Diabetes Obes Metab 2017;19:3.

This page is informational only and is not a personalized recommendation. The right choice depends on your individual situation.